scholarly journals OC09.06: Ultrasound imaging of fibroids in pregnancy: NICHD Fetal Growth Studies – singletons cohort

2021 ◽  
Vol 58 (S1) ◽  
pp. 30-30
Author(s):  
S.D. Mitro ◽  
Z. Chen ◽  
S. Peddada ◽  
G. Buck Louis ◽  
K. Fuchs ◽  
...  
2019 ◽  
Vol 221 (6) ◽  
pp. 635.e1-635.e16 ◽  
Author(s):  
Julio Mateus ◽  
Roger B. Newman ◽  
Cuilin Zhang ◽  
Sarah J. Pugh ◽  
Jagteshwar Grewal ◽  
...  

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Yeyi Zhu ◽  
Mengying Li ◽  
Stefanie Hinkle ◽  
Qi Sun ◽  
Jing Wu ◽  
...  

Abstract Objectives Polyunsaturated fatty acids (PUFAs) are essential for fetal growth and development, yet longitudinal data on objectively measured maternal PUFAs across pregnancy in relation to fetal growth remain elusive. We prospectively and longitudinally investigated plasma phospholipid PUFAs in pregnancy in relation to neonatal size and body composition. Methods Within the NICHD Fetal Growth Studies-Singleton Cohort (n = 2,802), individual plasma phospholipid PUFAs were measured in blood samples collected at gestational weeks (GW) 10–14, 15–26, 23–31, and 33–39 in a subset of 321 women. Birthweight (BW) was abstracted from medical records. Neonatal length and skinfolds were measured and fat mass (FM) and % body fat (BF) were estimated by Catalano's formula. We used linear regression models with robust variance and inverse probability weighting to standardize the sample. Results In late pregnancy at GW 33–39, after adjusting for covariates including prepregnancy body mass index, per unit increase in docosahexaenoic acid (DHA) was related to a 95.3 g (95% CI 33.6, 157.0) greater BW, 0.49 cm (0.09, 0.90) longer neonatal length, 41.2 g (13.6, 68.9) greater FM, and 0.79% (0.21, 1.37) higher BF. As for n-6 PUFAs, at GW 33–39, arachidonic acid per unit increase was associated with a 41.7 g (5.22, 78.3) greater BW and docosatetraenoic acid (DTA) per unit increase was related to a 462.3g (98.0, 826.6) and 145.5 g (12.1, 278.9) greater BW and FM, respectively. The PUFA n-6/n-3 ratio per unit increase at GW 33–39 was significantly related to a 14.6g (–29.2, –0.04) lower FM. Further, associations of n-3 PUFA with neonatal adiposity varied by prepregnancy obesity and exposure window. Total n-3 PUFA per unit increase at GW 23–31 and 33–39 was associated with 0.68-0.78% greater neonatal BF among women without obesity, whereas at GW 10–14 and 15–26 it was associated with 1.07–1.36% lower BF among women with obesity (P-interaction < 0.001). No significant associations were observed for individual PUFAs in early to mid-pregnancy with neonatal body composition, except for positive associations of DHA and DTA at GW 10–14 with BW. Conclusions Our data suggest that maternal plasma phospholipid PUFAs are implicated in fetal growth and their roles may vary by prepregnancy obesity and timing in pregnancy. Funding Sources NICHD/NIH.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1445-P
Author(s):  
MADHURA KISHOR DESHMUKH ◽  
HEMANT DAMLE ◽  
DATTATRAY BHAT ◽  
NILAM S. MEMANE ◽  
DEEPA A. RAUT ◽  
...  

Author(s):  
I.V. Komarova, A.A. Nikiforenko, A.V. Fedunyak

Literature reports of placental mosaicism, including trisomy 22, were analyzed. The chance of correlation of placental aneuploidy with fetus aneuploidy, also the probability of complications in pregnancy and fetal growth restriction and postnatal patients growth in the cases of confined placental mosaicism, were demonstrated. The case of prenatal diagnosis of confined placental mosaicism of trisomy 22 with favorable outcome is presented. The necessity of cytogenic assay of amniocytes and fetal lymphocytes in the case of placental heteroploidy diagnosis was emphasized.


2001 ◽  
Vol 185 (6) ◽  
pp. S175
Author(s):  
Radek Bukowski ◽  
Jim Zhang ◽  
Gayle Olson ◽  
J. Gardosi ◽  
George Saade

2017 ◽  
Vol 595 (15) ◽  
pp. 5095-5102 ◽  
Author(s):  
Elizabeth Cottrell ◽  
Teresa Tropea ◽  
Laura Ormesher ◽  
Susan Greenwood ◽  
Mark Wareing ◽  
...  

2018 ◽  
Vol 33 (1) ◽  
pp. 24-32
Author(s):  
Guoli Zhou ◽  
Claudia Holzman ◽  
Zhehui Luo ◽  
Claire Margerison

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Amanda J. Poprzeczny ◽  
Jennie Louise ◽  
Andrea R. Deussen ◽  
Jodie M. Dodd

Abstract Background The infants born to women who are overweight or obese in pregnancy are at an increased risk of being born macrosomic or large for gestational age. Antenatal dietary and lifestyle interventions have been shown to be ineffective at reducing this risk. Our aim was to examine the effects of metformin in addition to a diet and lifestyle intervention on fetal growth and adiposity among women with a BMI above the healthy range. Methods Women who had a body mass index ≥25 kg/m2 in early pregnancy, and a singleton gestation, were enrolled in the GRoW trial from three public maternity hospitals in metropolitan Adelaide. Women were invited to have a research ultrasounds at 28 and 36 weeks’ gestation at which ultrasound measures of fetal biometry and adiposity were obtained. Fetal biometry z-scores and trajectories were calculated. Measurements and calculations were compared between treatment groups. This secondary analysis was pre-specified. Results Ultrasound data from 511 women were included in this analysis. The difference in femur length at 36 weeks’ gestation was (0.07 cm, 95% CI 0.01–0.14 cm, p = 0.019) and this was was statistically significant, however the magnitude of effect was small. Differences between treatment groups for all other fetal biometry measures, z-scores, estimated fetal weight, and adiposity measures at 28 and 36 weeks’ gestation were similar. Conclusions The addition of metformin to dietary and lifestyle advice in pregnancy for overweight and obese women has no clinically relevant effect on ultrasound measures of fetal biometry or adiposity. Trial registration Australian and New Zealand Clinical Trials Registry (ACTRN12612001277831).


Sign in / Sign up

Export Citation Format

Share Document